RGEN Repligen Corp
Price (delayed)
$141.87
Market cap
$7.95B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.02
Enterprise value
$7.88B
Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in
Highlights
RGEN's quick ratio has surged by 176% year-on-year and by 6% since the previous quarter
The company's net income has shrunk by 113% QoQ and by 101% YoY
RGEN's EPS has dropped by 107% since the previous quarter and by 101% year-on-year
Key stats
What are the main financial stats of RGEN
Market
Valuations
Earnings
Shares outstanding
56.01M
Market cap
$7.95B
Enterprise value
$7.88B
Price to book (P/B)
3.99
Price to sales (P/S)
13.16
EV/EBIT
367.25
EV/EBITDA
85.69
EV/Sales
13.08
Revenue
$602.35M
EBIT
$21.46M
EBITDA
$91.95M
Free cash flow
$119.26M
Per share
Balance sheet
Liquidity
EPS
-$0.02
Free cash flow per share
$2.13
Book value per share
$35.55
Revenue per share
$10.78
TBVPS
$26.78
Total assets
$2.86B
Total liabilities
$875.56M
Debt
$742.85M
Equity
$1.99B
Working capital
$984.61M
Debt to equity
0.37
Current ratio
6.65
Quick ratio
5.35
Net debt/EBITDA
-0.72
Margins
Efficiency
Dividend
EBITDA margin
15.3%
Gross margin
42.5%
Net margin
-0.3%
Operating margin
1.2%
Return on assets
-0.1%
Return on equity
-0.1%
Return on invested capital
1.9%
Return on capital employed
0.8%
Return on sales
3.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGEN stock price
How has the Repligen stock price performed over time
Intraday
-1.07%
1 week
-2.27%
1 month
-13.27%
1 year
-10.14%
YTD
-21.1%
QTD
12.54%
Financial performance
How have Repligen's revenue and profit performed over time
Revenue
$602.35M
Gross profit
$255.88M
Operating income
$7.44M
Net income
-$1.9M
Gross margin
42.5%
Net margin
-0.3%
The net margin has plunged by 113% from the previous quarter and by 102% YoY
The company's net income has shrunk by 113% QoQ and by 101% YoY
The operating income has plunged by 95% YoY and by 71% from the previous quarter
The operating margin has plunged by 94% YoY and by 71% from the previous quarter
Growth
What is Repligen's growth rate over time
Valuation
What is Repligen stock price valuation
P/E
N/A
P/B
3.99
P/S
13.16
EV/EBIT
367.25
EV/EBITDA
85.69
EV/Sales
13.08
RGEN's EPS has dropped by 107% since the previous quarter and by 101% year-on-year
The P/B is 28% less than the 5-year quarterly average of 5.6 and 12% less than the last 4 quarters average of 4.6
RGEN's P/S is 24% below its 5-year quarterly average of 17.4 and 8% below its last 4 quarters average of 14.4
The revenue has contracted by 17% YoY
Efficiency
How efficient is Repligen business performance
RGEN's ROA has dropped by 117% since the previous quarter and by 102% year-on-year
The return on equity has dropped by 113% since the previous quarter and by 101% year-on-year
The ROIC has plunged by 91% YoY and by 49% from the previous quarter
RGEN's return on sales has dropped by 84% year-on-year and by 40% since the previous quarter
Dividends
What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGEN.
Financial health
How did Repligen financials performed over time
RGEN's quick ratio has surged by 176% year-on-year and by 6% since the previous quarter
Repligen's current ratio has surged by 149% YoY and by 4.7% QoQ
The debt is 63% less than the equity
The debt has soared by 76% YoY
Repligen's debt to equity has soared by 76% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.